UNIVERSITY OF MICHIGAN

Microdosing Ozempic, a diabetes medication, is a growing trend for weight loss, despite not being FDA-approved. Experts warn of risks like reduced effectiveness and potential misuse. Medical supervision is crucial, as sustained weight loss requires behavioral changes alongside medication.

About 1 in 3 U.S. adults have prediabetes, increasing risks for heart disease, stroke, and type 2 diabetes. The National Diabetes Prevention Program, initiated in 2010, aims to prevent type 2 diabetes through lifestyle changes. A study by University of Michigan researchers found participants saved ~$5,000 in medical costs over two years, with no significant change in quality-of-life but a lower probability of developing diabetes.

1 in 3 U.S. adults have prediabetes, risking heart disease, stroke, and type 2 diabetes. The National Diabetes Prevention Program, initiated in 2010, aims to prevent diabetes through lifestyle changes. A University of Michigan study found participants saved ~$5,000 in medical costs over two years, with no quality-of-life changes but reduced diabetes risk.

The 21st Century Cures Act mandates immediate patient access to medical test results, revealing a gap in understanding due to complex medical jargon. Research by Cathryn Lapedis shows patient-centered pathology reports significantly improve comprehension and reduce anxiety, advocating for their broader adoption to enhance patient care and communication.

Adolescent substance use has remained at lower levels for the fourth consecutive year post-COVID-19, with declines in alcohol, nicotine vaping, and cannabis use among certain grades. The Monitoring the Future Survey highlights stable or decreasing trends in drug use, emphasizing the need for continued research and intervention to sustain these positive trends.

Adolescent substance use has remained at lowered levels for four years post-COVID-19, with declines in alcohol, nicotine vaping, and cannabis use. The Monitoring the Future Survey highlights stable trends and some decreases in 2024, marking unprecedented reductions in teenage substance use.

By 31 January 2025, EU clinical trials must transition to CTIS. Key developments include Roche's Prasinezumab for Parkinson's, Teva and Sanofi's Duvakitug for ulcerative colitis, and Amgen's Imdyllytra for lung cancer. AI's role in drug development and the UK's growing clinical trial appeal are noted. APAC leads in Parkinson's trials.

Increased patient access to medical test results is causing confusion and anxiety due to jargon-filled reports. A study suggests patient-friendly reports improve understanding, with 93% accurately identifying prostate cancer from such reports, compared to 39% with standard reports. Researchers recommend hospitals include patient-centered reports to enhance comprehension.

In 2024, key topics included opioid access, new pain treatments, and chronic pain management. Highlights included Ella Emhoff's chronic pain advocacy, DEA's opioid production cuts, and challenges in filling opioid prescriptions. Research on doctors' reluctance to accept opioid or cannabis users and an experimental hydrocodone formulation were also notable.

NIH study links brain structure differences in adolescents to early substance use, suggesting these differences may predate use and influence risk, alongside genetic and environmental factors.